Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning

8 Apr 2023

Abstract excerpt

Response to androgen receptor signaling inhibitors (ARSI) varies widely in metastatic castration resistant prostate cancer (mCRPC). To improve treatment guidance, biomarkers are needed. We use whole-genomics (WGS; n = 155) with matching whole-transcriptomics (WTS; n = 113) from biopsies of ARSI-treated mCRPC patients for unbiased discovery of biomarkers and development of machine learning-based prediction models....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Prostate Cancer Treatment and Research
Share to Radiopharmaceutical Chemistry and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37031196
DOI: 10.1038/s41467-023-37647-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learningPMID 37031196Read ↗

Genomic correlates of clinical outcome in advanced prostate cancerSemantic proximity Read ↗

A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancerSemantic proximity Read ↗

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.Semantic proximity Read ↗

Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease ProgressionSemantic proximity Read ↗

Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

Comparison of Whole Genome Sequencing with Clinical Targeted Panel Sequencing of Metastatic Prostate Cancer: Insights from Real- World DataSemantic proximity Read ↗

Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone TreatmentSemantic proximity Read ↗

Integrative clinical genomics of advanced prostate cancer.Semantic proximity Read ↗

Comparison of whole genome sequencing with clinical targeted panel sequencing of metastatic prostate cancer: insights from real-world dataSemantic proximity Read ↗

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate CancerSemantic proximity Read ↗

Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.